Eftichia Kritsi, Chemist, MSc., Ph.D.

E-mail: ekritsi@eie.gr; **Scopus Author ID:** 52163993900, ***h*-index**: 7

Education

2017: Ph.D. School of Chemical Engineering, National Technical University of Athens (NTUA)
2012: M.Sc. Organic Chemistry, Chemistry Department, National & Kapodistrian University of Athens (UOA)
2010: B.Sc. Chemistry Department, National and Kapodistrian University of Athens (UOA)

Current Research Interests

Discovery of bioactive compounds, using advanced *in silico* methodologies (pharmacophore modeling, conformational studies, virtual screening, Molecular Dynamics simulations) complemented with analytical techniques, mainly NMR spectroscopy.

Main achievements

Literature contribution: 23 Peer-reviewed scientific articles; **20** Announcements; **3** Oral presentations

Participation in funding programs:

12.2018-08.2020: Postdoctoral researcher, "**DINNESMIN**", **RESEARCH-CREATE–INNOVATE**, Preclinical development of innovative neuro-protective and neuro-regenerative synthetic microneurotrophins against Alzheimer disease, (EPAnEK2014-2020), Institute of Chemical Biology (ICB), National Hellenic Research Foundation (NHRF).

12-06.2018 and 08-11.2019: Postdoctoral researcher, **KRIPIS II–Sthenos-β**: Targeted therapeutic approaches against degenerative diseases-conditions with emphasis in cancer and aging, (EPAN II2018-2021), ICB, NHRF.

09-11.2015: Ph.D candidate, **KRIPIS I-Sthenos**: Targeted therapeutic approaches against degenerative diseases-conditions with emphasis in cancer and aging, (EPANI 2013-2015), ICB, NHRF.

Scholarships:

02.2020-02.2022: Postdoctoral researcher fellowship, "Reinforcement of Postdoctoral Researchers - 2nd Cycle" (MIS-5033021), the State Scholarships Foundation (IKY), *"A combinatorial methodology for the discovery of epigenetics inhibitors"*.

04-08.2017: Postgraduate fellowship, "IKY FELLOWSHIPS OF EXELLENCE FOR POSTGRATUATE STUDIES IN GREECE-SIEMENS PROGRAMM'', "*Discovery of new hit compounds targeting Odorant Binding proteins (OBPs) as putative repellents"*.

2013-2014: Postgraduate fellowship, C. Karatheodory_2010 program: *"Exploring the biological and anticancer properties of the neurohypophysial hormone oxytocin via studying its structural analogs".*

Teaching experience:

2019-2020: Lecturer in 2 M.Sc. programs: Oncology: from oncogenesis to therapy (University of Crete/NHRF), BIOENTREPRENEURSHIP (University of Thessaly/NHRF); Academic fellow, Department of Food Science and Technology, School of Food Sciences, University of West Attica (UniWA); Organization of 2 workshops

Highlighted Publications in Peer Reviewed Scientific Journals

(1) E. Kritsi, M. T. Matsoukas, C. Potamitis, V. Karageorgos, A. Detsi, M. Ivanov, M. Sokovic, P. Zoumpoulakis, Novel Hit Compounds as Putative Antifungals: The Case of *Aspergillus fumigatus*, *Molecules*, 24 (21), 3853, 2019. **DOI:** 10.3390/molecules24213853 (IF 2018/2019: 3.060)

(2) J. Zachmann, **E. Kritsi**, A. Tapeinou, P. Zoumpoulakis, T. Tselios, M. T. Matsoukas, A Combined Computational and Structural Approach into Understanding the Role of Peptide Binding and Activation of the Melanocortin Receptor 4, *J. Chem. Inf. Model*, 60 (3), 1461-1468, 2020. **DOI:** 10.1021/acs.jcim.9b01196 (IF 2018/2019: 3.966)

(3) E. Kritsi, M. T. Matsoukas, C. Potamitis, V. Karageorgos, A. Detsi, V. Magafa, G. Liapakis, T. Mavromoustakos, P. Zoumpoulakis, Exploring new scaffolds for angiotensin II receptor antagonism, *Bioorg. Med. Chem.,* 24 (18), 4444-4451, 2016. **DOI:** 10.1016/j.bmc.2016.07.047 (IF 2018/2019: 2.793)

(4) D. Xanthopoulos, **E. Kritsi**, C. T. Supuran, M. G. Papadopoulos, G. Leonis, P. Zoumpoulakis, Discovery of HIV Type 1 Aspartic Protease Hit Compounds through Combined Computational Approaches, *Chem. Med. Chem.,* 11 (15), 1646-1652, 2016. **DOI:** 10.1002/cmdc.201600220 (IF 2018/2019: 3.016)

(5) M. Smilijkovic, M. T. Matsoukas, **E. Kritsi**, U. Zelenko, S. Golic Grdadolnik, R. C. Calhelha, I. C. F. R. Ferreira, S. Sankovic-Babic, J. Glamoclija, T. Fotopoulou, M. Koufaki, P. Zoumpoulakis, M. Sokovic, Nitrate esters of heteroaromatic compounds as novel Candida albicans CYP51 enzyme inhibitors, *Chem. Med. Chem.*, 13 (3), 251-258, 2018. **DOI:** 10.1002/cmdc.201700602 (IF 2018/2019: 3.016)